Golden
Abraxis BioScience

Abraxis BioScience

A Biopharmaceutical company based in Los Angeles and founded in 2007 that develops therapeutics and technologies using nanotechnology for cancer and other critical illnesses.

All edits

Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+3 properties)
Edits on 30 Mar 2019
Dawson Sewell
Dawson Sewell edited on 30 Mar 2019 6:08 pm
Edits made to:
Infobox (+2 properties)
Description (+18 characters)
Topic thumbnail

Abraxis BioScience

A Biopharmaceutical company based in Los Angeles and founded in 2007 that develops therapeutics and technologies using nanotechnology for cancer and other critical illnesses.

Infobox

Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 1:14 pm
Edits made to:
Infobox (+10 properties)
Timeline (+1 events) (+219 characters)
Article (+721/-501 characters)
Further reading (+4 cells) (+171 characters)
Related Topics (+2 topics)

Article

Abraxis was acquired by Celgene in 2010. Abraxane is the brand name for the nanoparticle chemotherapeutic compound developed by Abraxis using its proprietary tumor targeting nanoparticle albumin-bound (nab) technology to treat metastatic breast cancer.



In 2005 Abraxis became the first nanodrug approved by the FDA. Generic forms of this drug are called Nab-paclitaxel and along with breast cancer the chemotherapy drug is also used to treat pancreatic cancer and non small cell lung cancer.



Abraxis was acquired by Celgene in 2010. Abraxane is the brand name for the nanoparticle chemotherapeutic compound developed by Abraxis using its proprietary tumor targeting nanoparticle albumin-bound (nab) technology to treat metastatic breast cancer. In 2005 Abraxis became the first nanodrug approved by the FDA. Generic forms of this drug are called Nab-paclitaxel and along with breast cancer the chemotherapy drug is also used to treat pancreatic cancer and non small cell lung cancer.PaclitaxelPaclitaxel inhibits cell mitosis which prevents cells from multiplying but its hydrophobic nature meant that toxic solvents were needed to deliver the treatment. Linking the drug to albumin, which is carried in the blood, allows it to be delivered without solvents so that higher doses are tolerated.Tumors are effectively targeted due to their affinity for albumin. 

...

Acquired by Celegene

On June 30, 2010 Abraxis BioScience made an agreement to be acquired by the biotechnology company Celgene for $2.9 billion dollars at an implied price of $71.93 per share of Abrixis BioScience stock. 

Further reading

Infobox

Related Topics

Timeline

June 30, 2010

Acquired by Celgene

On June 30, 2010 Abraxis BioScience made an agreement to be acquired by the biotechnology company Celgene for $2.9 billion dollars at an implied price of $71.93 per share of Abrixis BioScience stock. 

Edits on 12 Feb 2019
Golden AI"Import data"
Golden AI edited on 12 Feb 2019 12:40 am
Edits made to:
Infobox (+1 properties)
Edits on 8 Feb 2019
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 8 Feb 2019 1:30 am
Edits made to:
Infobox (+3 properties)
People (+22 cells) (+230 characters)

People

Name
Role
Related Golden topics

Aaron Kaufman

Employee



Ata Ghofrani

Employee



Bianca Anderson

Employee



Craig Lauer

Employee



Dave Adams

Employee



Jacki Petrovic

Employee



Joe Hogan

Employee



Lauren Weiniger

Employee



Paula Brunelle

Employee



Sanjay Gupta

Employee



Stephannie Perrin

Employee



Infobox

Edits on 30 Nov 2018
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 30 Nov 2018 3:12 am
Edits made to:
Article (+7/-7 characters)

Article

Abraxis was acquired by CelgeneCelgene in 2010. Abraxane is the brand name for the nanoparticle chemotherapeutic compound developed by Abraxis using its proprietary tumor targeting nanoparticle albumin-bound (nab) technology to treat metastatic breast cancer. In 2005 Abraxis became the first nanodrug approved by the FDA. Generic forms of this drug are called Nab-paclitaxel and along with breast cancer the chemotherapy drug is also used to treat pancreatic cancer and non small cell lung cancer.Paclitaxel inhibits cell mitosis which prevents cells from multiplying but its hydrophobic nature meant that toxic solvents were needed to deliver the treatment. Linking the drug to albumin, which is carried in the blood, allows it to be delivered without solvents so that higher doses are tolerated.Tumors are effectively targeted due to their affinity for albumin. 

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 30 Nov 2018 3:10 am
Edits made to:
Article (+11/-11 characters)

Article

Abraxis was acquired by Celgene in 2010. Abraxane is the brand name for the nanoparticle chemotherapeutic compound developed by Abraxis using its proprietary tumor targeting nanoparticle albumin-bound (nab) technology to treat metastatic breast cancer. In 2005 Abraxis became the first nanodrug approved by the FDA. Generic forms of this drug are called Nab-paclitaxel and along with breast cancer the chemotherapy drug is also used to treat pancreatic cancer and non small cell lung cancerlung cancer.Paclitaxel inhibits cell mitosis which prevents cells from multiplying but its hydrophobic nature meant that toxic solvents were needed to deliver the treatment. Linking the drug to albumin, which is carried in the blood, allows it to be delivered without solvents so that higher doses are tolerated.Tumors are effectively targeted due to their affinity for albumin. 

Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 30 Nov 2018 1:52 am
Edits made to:
Article (+17/-17 characters)

Article

Abraxis was acquired by Celgene in 2010. Abraxane is the brand name for the nanoparticle chemotherapeutic compound developed by Abraxis using its proprietary tumor targeting nanoparticle albumin-bound (nab) technology to treat metastatic breast cancer. In 2005 Abraxis became the first nanodrug approved by the FDA. Generic forms of this drug are called Nab-paclitaxel and along with breast cancer the chemotherapy drug is also used to treat pancreatic cancerpancreatic cancer and non small cell lung cancer.Paclitaxel inhibits cell mitosis which prevents cells from multiplying but its hydrophobic nature meant that toxic solvents were needed to deliver the treatment. Linking the drug to albumin, which is carried in the blood, allows it to be delivered without solvents so that higher doses are tolerated.Tumors are effectively targeted due to their affinity for albumin. 

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 30 Nov 2018 1:30 am
Edits made to:
Article (+10/-10 characters)

Article

Abraxis was acquired by Celgene in 2010. Abraxane is the brand name for the nanoparticle chemotherapeutic compound developed by Abraxis using its proprietary tumor targeting nanoparticle albumin-bound (nab) technology to treat metastatic breast cancer. In 2005 Abraxis became the first nanodrug approved by the FDA. Generic forms of this drug are called Nab-paclitaxel and along with breast cancer the chemotherapy drug is also used to treat pancreatic cancer and non small cell lung cancer.PaclitaxelPaclitaxel inhibits cell mitosis which prevents cells from multiplying but its hydrophobic nature meant that toxic solvents were needed to deliver the treatment. Linking the drug to albumin, which is carried in the blood, allows it to be delivered without solvents so that higher doses are tolerated.Tumors are effectively targeted due to their affinity for albumin. 

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 30 Nov 2018 1:29 am
Edits made to:
Article (+13/-13 characters)

Article

Abraxis was acquired by Celgene in 2010. Abraxane is the brand name for the nanoparticle chemotherapeutic compound developed by Abraxis using its proprietary tumor targeting nanoparticle albumin-bound (nab) technology to treat metastatic breast cancerbreast cancer. In 2005 Abraxis became the first nanodrug approved by the FDA. Generic forms of this drug are called Nab-paclitaxel and along with breast cancer the chemotherapy drug is also used to treat pancreatic cancer and non small cell lung cancer.Paclitaxel inhibits cell mitosis which prevents cells from multiplying but its hydrophobic nature meant that toxic solvents were needed to deliver the treatment. Linking the drug to albumin, which is carried in the blood, allows it to be delivered without solvents so that higher doses are tolerated.Tumors are effectively targeted due to their affinity for albumin. 

Edits on 28 Nov 2018
Meredith Hanel
Meredith Hanel edited on 28 Nov 2018 2:35 am
Edits made to:
Description (+66/-2 characters)
Article (+988 characters)
Categories (+1 topics)
Topic thumbnail

Abraxis BioScience

A company based in Los Angeles and founded in 2007 that develops therapeutics and technologies tousing nanotechnology for cancer and other critical illnesses.

Article

Abraxis was acquired by Celgene in 2010. Abraxane is the brand name for the nanoparticle chemotherapeutic compound developed by Abraxis using its proprietary tumor targeting nanoparticle albumin-bound (nab) technology to treat metastatic breast cancer. In 2005 Abraxis became the first nanodrug approved by the FDA. Generic forms of this drug are called Nab-paclitaxel and along with breast cancer the chemotherapy drug is also used to treat pancreatic cancer and non small cell lung cancer.Paclitaxel inhibits cell mitosis which prevents cells from multiplying but its hydrophobic nature meant that toxic solvents were needed to deliver the treatment. Linking the drug to albumin, which is carried in the blood, allows it to be delivered without solvents so that higher doses are tolerated.Tumors are effectively targeted due to their affinity for albumin. 

...

Other clinical products being developed use nanotechnology to treat cancers, coronary restenosis and peripheral artery restenosis.

Categories

Edits on 13 Sep 2018
Golden AI"Import structured data from Wikidata.org: https://www.wikidata.org/wiki/Q4669505"
Golden AI edited on 13 Sep 2018 6:15 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 1 Sep 2018
Golden AI"Update description"
Golden AI edited on 1 Sep 2018 12:12 am
Edits made to:
Description (+92/-21 characters)
Topic thumbnail

Abraxis BioScience

Biotechnology company

A company that develops therapeutics and technologies to cancer and other critical illnesses

Edits on 3 Aug 2018
Jude Gomila
Jude Gomila edited on 3 Aug 2018 12:37 pm
Edits made to:
Topic thumbnail

Abraxis BioScience

A Biopharmaceutical company based in Los Angeles and founded in 2007 that develops therapeutics and technologies using nanotechnology for cancer and other critical illnesses.

Jude Gomila
Jude Gomila edited on 3 Aug 2018 12:37 pm
Edits made to:
Description (+21 characters)
Topic thumbnail

Abraxis BioScience

Biotechnology company

Edits on 1 Jan 2017
Golden AI"Initial topic creation"
Golden AI created this topic on 1 Jan 2017 12:00 am
Edits made to:
Article
Topic thumbnail

 Abraxis BioScience

A Biopharmaceutical company based in Los Angeles and founded in 2007 that develops therapeutics and technologies using nanotechnology for cancer and other critical illnesses.

No more activity to show.